Vitrivax Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
52
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$87M
- Investors
-
15
Vitrivax General Information
Description
Developer of thermostable vaccine formulations designed to eliminate barriers to global vaccination. The company offers a proprietary atomic-layering thermostable antigen and adjuvant technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response, enabling users to incorporate prime doses and additional booster doses in a single-shot administration.
Contact Information
Website
vitrivaxbio.comCorporate Office
- 5500 Central Avenue
- Suite 220
- Boulder, CO 80301
- United States
Corporate Office
- 5500 Central Avenue
- Suite 220
- Boulder, CO 80301
- United States
Vitrivax Timeline
Vitrivax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series C) | 19-Nov-2026 | $87M | Completed | Generating Revenue | ||
| 9. Later Stage VC (Series B) | 17-Nov-2025 | Completed | Generating Revenue | |||
| 8. Grant | 14-Oct-2025 | Completed | Generating Revenue | |||
| 7. Grant | 28-Apr-2025 | Completed | Generating Revenue | |||
| 6. Grant | 04-Dec-2024 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 4. Grant | 06-Dec-2023 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 10-Apr-2023 | Completed | Generating Revenue | |||
| 2. Grant | 22-May-2020 | $240K | Completed | Generating Revenue | ||
| 1. University Spin-Out | 01-Jan-2014 | Completed | Generating Revenue |
Vitrivax Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B-2 | ||||||||
| Series A | 5,057,582 | $0.001000 | $1.85 | $1.85 | 1x | $1.85 | 15.25% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Vitrivax Comparisons
Industry
Financing
Details
Vitrivax Competitors (1)
One of Vitrivax’s competitors is iQ Biosciences, a Accelerator/Incubator Backed company based in Alameda, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| iQ Biosciences | Accelerator/Incubator Backed | Alameda, CA |
Vitrivax Patents
Vitrivax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165138-A2 | Compositions and methods for reducing agglomeration of microparticles in coating processes | Pending | 31-Jan-2025 | ||
| WO-2026165138-A3 | Compositions and methods for reducing agglomeration of microparticles in coating processes | Pending | 31-Jan-2025 | ||
| US-20260325460-A1 | Compositions, methods and uses for determining atomic layer deposition coating quality and dissolution rates | Pending | 04-Dec-2023 | ||
| WO-2025122516-A1 | Compositions, methods and uses for determining atomic layer deposition coating quality and dissolution rates | Inactive | 04-Dec-2023 | ||
| JP-2026526606-A | Composition, method, and use of polynucleotide preparations for drying and long-term storage | Pending | 28-Jul-2023 | A61K9/5123 |
Vitrivax Signals
Vitrivax Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eli Lilly Canada | Corporation | Minority | ||
| F-Prime | Venture Capital | Minority | ||
| Nea | Venture Capital | Minority | ||
| Sanofi Ventures | Corporate Venture Capital | Minority | ||
| RA Capital Management | Asset Manager | Minority |
Vitrivax FAQs
-
When was Vitrivax founded?
Vitrivax was founded in 2014.
-
Where is Vitrivax headquartered?
Vitrivax is headquartered in Boulder, CO.
-
What is the size of Vitrivax?
Vitrivax has 52 total employees.
-
What industry is Vitrivax in?
Vitrivax’s primary industry is Biotechnology.
-
Is Vitrivax a private or public company?
Vitrivax is a Private company.
-
What is Vitrivax’s current revenue?
The current revenue for Vitrivax is .
-
How much funding has Vitrivax raised over time?
Vitrivax has raised $125M.
-
Who are Vitrivax’s investors?
Eli Lilly Canada, F-Prime, Nea, Sanofi Ventures, and RA Capital Management are 5 of 15 investors who have invested in Vitrivax.
-
Who are Vitrivax’s competitors?
iQ Biosciences is a competitor of Vitrivax.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process